Gail S. Kerr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gail S. Kerr has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Ted R. Mikuls
University of Nebraska Medical Center Omaha
9 shared publications - Grant W. Cannon
VA Salt Lake City Health Care System and University of Utah Salt Lake City
8 shared publications - Bryant R. England
VA Nebraska‐Western Iowa Health Care System and University of Nebraska Medical Center Omaha Nebraska
6 shared publications Gary Kunkel
Salt Lake City VA Health Care System Salt Lake City Utah
6 shared publicationsJoshua F. Baker
Corporal Michael J. Crescenz VA Medical Center Philadelphia Pennsylvania
5 shared publications- Katherine D. Wysham
VA Puget Sound Health Care System & University of Washington , Seattle, WA
5 shared publications
Latest Publications
- 15 September 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Patient-Reported Outcomes Following Discontinuation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Remission/Low Disease Activity: A Randomized Placebo-Controlled Trial
Objective: To compare changes in patient-reported outcomes (PROs) over 48 weeks between patients with rheumatoid arthritis (RA) in remission/low disease activity who discontinued treatment with tumor necrosis factor inhibitors (TNFi) and those who continued TNFi treatment. Methods: In this randomized, double-blind, placebo-controlled trial, patients with RA in sustained remission/ low disease activity treated with TNFi were randomly assigned to placebo (ie, discontinuation of TNFi) or continuation of TNFi. Patients completed PROs, including the patient global assessment (PtGA), pain scale, Health Assessment Questionnaire–Disability Index (HAQ-DI), Fatigue Severity Scale, and 36-item Short Form Health Survey (SF-36), at randomization and every 12 weeks for 48 weeks. We compared PROs over time between treatment groups using generalized estimating equations. We also compared mean changes from baseline at each timepoint and separately among patients who relapsed. Results: Sixty-nine patients were randomized to placebo and 33 patients were randomized to the TNFi group. Over the trial, group mean scores on the PtGA, pain score, and HAQ-DI were significantly higher in the placebo group than in the TNFi group. Effect sizes were small or moderate for all PROs. Compared with week 0, all measures were significantly higher in the placebo group at week 12, but not at later times, in paired analyses, corresponding to the timing of most relapses. SF-36 bodily pain and social function were the domains most affected. PROs returned to baseline values by trial end after resuming TNFi treatment. Conclusion: PROs generally worsened shortly after TNFi discontinuation in patients with RA but recovered promptly when reinstituted. (ClinicalTrials.gov: NCT01793519 )
- 15 September 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Patient-Reported Outcomes Following Discontinuation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Remission/Low Disease Activity: A Randomized Placebo-Controlled Trial
Objective: To compare changes in patient-reported outcomes (PROs) over 48 weeks between patients with rheumatoid arthritis (RA) in remission/low disease activity who discontinued treatment with tumor necrosis factor inhibitors (TNFi) and those who continued TNFi treatment. Methods: In this randomized, double-blind, placebo-controlled trial, patients with RA in sustained remission/ low disease activity treated with TNFi were randomly assigned to placebo (ie, discontinuation of TNFi) or continuation of TNFi. Patients completed PROs, including the patient global assessment (PtGA), pain scale, Health Assessment Questionnaire–Disability Index (HAQ-DI), Fatigue Severity Scale, and 36-item Short Form Health Survey (SF-36), at randomization and every 12 weeks for 48 weeks. We compared PROs over time between treatment groups using generalized estimating equations. We also compared mean changes from baseline at each timepoint and separately among patients who relapsed. Results: Sixty-nine patients were randomized to placebo and 33 patients were randomized to the TNFi group. Over the trial, group mean scores on the PtGA, pain score, and HAQ-DI were significantly higher in the placebo group than in the TNFi group. Effect sizes were small or moderate for all PROs. Compared with week 0, all measures were significantly higher in the placebo group at week 12, but not at later times, in paired analyses, corresponding to the timing of most relapses. SF-36 bodily pain and social function were the domains most affected. PROs returned to baseline values by trial end after resuming TNFi treatment. Conclusion: PROs generally worsened shortly after TNFi discontinuation in patients with RA but recovered promptly when reinstituted. (ClinicalTrials.gov: NCT01793519 )
- Open Access
- 9 June 2026
- Published by Wiley in Arthritis & Rheumatology
Fine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General‐Population Cohort Analysis With Extended Quantile g‐Computation
Objective: The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM 2.5 ) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset. Methods: We used MarketScan claims data to assemble a cohort of adults with at least two years’ insurance coverage and no prior SLE diagnosis, with cohort entry defined as the first qualifying date. From this full cohort, we identified all people with incident SLE and a 20% random sample, yielding a case‐cohort of 8.3 million people. Concentrations of ozone and seven PM 2.5 constituents (ammonium, black carbon, mineral dust, sulfate, nitrate, organic matter, and sea salt) were estimated at the core‐based statistical area/metropolitan‐division level. Mean annual exposures for the two years before cohort entry were assigned to each person. Extended quantile g‐computation produced hazard ratios (HRs) for the PM 2.5 mixture and weights (ie, relative contributions to SLE onset) for individual constituents, adjusting for sex, age, chronic obstructive pulmonary disease, geographic region, and calendar year. Results: We identified 21,485 people with newly diagnosed SLE. At the median ozone level (36.15 parts per billion [ppb]), each quartile increase of PM 2.5 mixture was associated with an HR of 1.14 (95% confidence interval [CI] 1.11–1.18) for SLE risk; mineral dust dominated this effect. Ozone was associated with SLE risk (HR 1.009 per 1 ppb, 95% CI 1.001–1.017). PM 2.5 's effect was particularly strong in settings of low ozone. Conclusion: This study demonstrated how PM 2.5 constituents (especially mineral dust) and ozone are associated with SLE incidence.
- 9 June 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessFine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General‐Population Cohort Analysis With Extended Quantile g‐Computation
Objective: The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM 2.5 ) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset. Methods: We used MarketScan claims data to assemble a cohort of adults with at least two years’ insurance coverage and no prior SLE diagnosis, with cohort entry defined as the first qualifying date. From this full cohort, we identified all people with incident SLE and a 20% random sample, yielding a case‐cohort of 8.3 million people. Concentrations of ozone and seven PM 2.5 constituents (ammonium, black carbon, mineral dust, sulfate, nitrate, organic matter, and sea salt) were estimated at the core‐based statistical area/metropolitan‐division level. Mean annual exposures for the two years before cohort entry were assigned to each person. Extended quantile g‐computation produced hazard ratios (HRs) for the PM 2.5 mixture and weights (ie, relative contributions to SLE onset) for individual constituents, adjusting for sex, age, chronic obstructive pulmonary disease, geographic region, and calendar year. Results: We identified 21,485 people with newly diagnosed SLE. At the median ozone level (36.15 parts per billion [ppb]), each quartile increase of PM 2.5 mixture was associated with an HR of 1.14 (95% confidence interval [CI] 1.11–1.18) for SLE risk; mineral dust dominated this effect. Ozone was associated with SLE risk (HR 1.009 per 1 ppb, 95% CI 1.001–1.017). PM 2.5 's effect was particularly strong in settings of low ozone. Conclusion: This study demonstrated how PM 2.5 constituents (especially mineral dust) and ozone are associated with SLE incidence.
- Open Access
- 24 February 2026
- Published by Wiley in Arthritis Care & Research
Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis–Associated Interstitial Lung Disease Risk
Objective: The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase‐7 (MMP‐7), and serum anti–malondialdehyde‐acetaldehyde (anti‐MAA) antibody for rheumatoid arthritis (RA)–associated interstitial lung disease (ILD) risk stratification. Methods: Using a multicenter cohort of US veterans with RA, we performed a cross‐sectional study of prevalent RA‐ILD and a cohort study of incident RA‐ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three‐biomarker score (range 0–3) was calculated based on the presence of the MUC5B variant and elevations (upper 25% vs lower 75%) in MMP‐7 and anti‐MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors. Results: Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male; mean age 63.6 years). The odds of prevalent RA‐ILD were higher with increased biomarker score (adjusted odds ratio 12.21 [95% confidence interval (CI) 3.82–38.97] for score of 3 vs 0). A score ≥1 had 76.1% sensitivity but 48.6% specificity. Incident RA‐ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (adjusted hazard ratio 4.36 [95% CI 1.55–12.27]). The area under the curve for prevalent RA‐ILD and Harrell's C for incident RA‐ILD were highest when clinical risk factors were combined with the biomarker score. Conclusion: This three‐analyte biomarker score was associated with both prevalent and incident RA‐ILD, improving risk stratification beyond clinical risk factors. Although this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA‐ILD risk stratification.
- 24 February 2026
- Published by Wiley in Arthritis Care & Research
Open AccessCombining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis–Associated Interstitial Lung Disease Risk
Objective: The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase‐7 (MMP‐7), and serum anti–malondialdehyde‐acetaldehyde (anti‐MAA) antibody for rheumatoid arthritis (RA)–associated interstitial lung disease (ILD) risk stratification. Methods: Using a multicenter cohort of US veterans with RA, we performed a cross‐sectional study of prevalent RA‐ILD and a cohort study of incident RA‐ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three‐biomarker score (range 0–3) was calculated based on the presence of the MUC5B variant and elevations (upper 25% vs lower 75%) in MMP‐7 and anti‐MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors. Results: Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male; mean age 63.6 years). The odds of prevalent RA‐ILD were higher with increased biomarker score (adjusted odds ratio 12.21 [95% confidence interval (CI) 3.82–38.97] for score of 3 vs 0). A score ≥1 had 76.1% sensitivity but 48.6% specificity. Incident RA‐ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (adjusted hazard ratio 4.36 [95% CI 1.55–12.27]). The area under the curve for prevalent RA‐ILD and Harrell's C for incident RA‐ILD were highest when clinical risk factors were combined with the biomarker score. Conclusion: This three‐analyte biomarker score was associated with both prevalent and incident RA‐ILD, improving risk stratification beyond clinical risk factors. Although this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA‐ILD risk stratification.
- Open Access
- 11 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (2) , 302-310
Performance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease
Objective: To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) using three independent cohorts. Methods: We first assessed the association of a panel of IPF‐associated biomarkers with prevalent ILD among two separate RA cohorts (n = 93 and n = 71). Concentrations of eight IPF‐related biomarkers (eotaxin, Flt‐3L, interleukin‐8, macrophage‐derived chemokine, monocyte chemoattractant protein 1, and matrix metalloproteinase 2/7/9 [MMP‐2/7/9]) were measured, standardized, and summed to generate a multibiomarker score. We subsequently validated the association of this score (minus MMP‐2) with prevalent and incident ILD in an independent multicenter prospective cohort of US veterans with RA (n = 2,507). Multivariable regression models were adjusted for relevant covariates in the validation cohort. Results: In both development cohorts, participants with RA‐ILD had significantly higher IPF multibiomarker scores than those with RA alone. In the independent validation cohort, participants in the highest quartile of multibiomarker scores had a significantly higher likelihood of prevalent ILD (adjusted odds ratio 2.14 [95% confidence interval 1.18–3.87]) and incident ILD (adjusted hazard ratio 2.45 [95% confidence interval 1.55–3.88]) than those in the lowest quartile. The cumulative hazard of incident ILD approached 20% by 15 years for those in the highest quartile, compared to <10% for all other quartiles. Conclusion: A multibiomarker panel derived from IPF‐associated biomarkers was associated with RA‐ILD in separate development and validation cohorts. This overlap supports the concept of shared etiopathogenesis of IPF and RA‐ILD and illustrates the potential for peripheral blood biomarker panels to stratify ILD risk among patients with RA.
- 11 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (2) , 302-310
Open AccessPerformance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease
Objective: To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) using three independent cohorts. Methods: We first assessed the association of a panel of IPF‐associated biomarkers with prevalent ILD among two separate RA cohorts (n = 93 and n = 71). Concentrations of eight IPF‐related biomarkers (eotaxin, Flt‐3L, interleukin‐8, macrophage‐derived chemokine, monocyte chemoattractant protein 1, and matrix metalloproteinase 2/7/9 [MMP‐2/7/9]) were measured, standardized, and summed to generate a multibiomarker score. We subsequently validated the association of this score (minus MMP‐2) with prevalent and incident ILD in an independent multicenter prospective cohort of US veterans with RA (n = 2,507). Multivariable regression models were adjusted for relevant covariates in the validation cohort. Results: In both development cohorts, participants with RA‐ILD had significantly higher IPF multibiomarker scores than those with RA alone. In the independent validation cohort, participants in the highest quartile of multibiomarker scores had a significantly higher likelihood of prevalent ILD (adjusted odds ratio 2.14 [95% confidence interval 1.18–3.87]) and incident ILD (adjusted hazard ratio 2.45 [95% confidence interval 1.55–3.88]) than those in the lowest quartile. The cumulative hazard of incident ILD approached 20% by 15 years for those in the highest quartile, compared to <10% for all other quartiles. Conclusion: A multibiomarker panel derived from IPF‐associated biomarkers was associated with RA‐ILD in separate development and validation cohorts. This overlap supports the concept of shared etiopathogenesis of IPF and RA‐ILD and illustrates the potential for peripheral blood biomarker panels to stratify ILD risk among patients with RA.
- 17 September 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 75, 152831
Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial
- 17 September 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 75, 152831
Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial
- Open Access
- 8 August 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (11) , 1350-1358
Agreement of Administrative Pharmacy Dispensing With Self‐Reported Use of Oral Prednisone in US Veterans With Rheumatoid Arthritis
Objective: Administrative claims are used to evaluate oral glucocorticoid use in rheumatoid arthritis (RA), despite limited evidence to support accuracy. We aimed to evaluate the performance of claims‐based algorithms for glucocorticoid use compared to self‐report in an RA population. Methods: Participants with RA enrolled at seven Veterans Affairs Rheumatoid Arthritis (VARA) Registry sites were asked six questions as part of clinical care assessing current prednisone use and dose, recent use, “stockpiling,” and receiving prednisone outside the Department of Veterans Affairs (VA). Algorithms using VA prescription claims operationalized current use (active prescription on date of self‐report assessment), current dose (that prescription's mean dose), and recent use (active course overlapping the prior 30 or 90 days). We assessed performance characteristics and agreement, benchmarked on self‐report. Results: Of 284 participants, 13% reported current prednisone use and 20% reported 90‐day use. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.70, 0.98, 0.84, and 0.96, respectively, for current use and 0.71, 0.92, 0.72, and 0.92, respectively, for 90‐day use. Cohen's κ was 0.68 for current use and 0.63 for 90‐day use. Among participants reporting ≤5 mg/day, agreement for dose was high (weighted κ 0.67). One in four participants reported a stockpile, and one in four reported receiving prednisone from a non‐VA provider. Conclusion: Algorithms derived from VA claims detecting prednisone prescriptions have high validity compared to patient self‐report. The modest sensitivity of these algorithms may reflect stockpiling and non‐VA prescriptions. These findings form a basis for contextualizing real‐world studies of glucocorticoid use in RA and improve clinical estimation of glucocorticoid use not captured in claims.
- 8 August 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (11) , 1350-1358
Open AccessAgreement of Administrative Pharmacy Dispensing With Self‐Reported Use of Oral Prednisone in US Veterans With Rheumatoid Arthritis
Objective: Administrative claims are used to evaluate oral glucocorticoid use in rheumatoid arthritis (RA), despite limited evidence to support accuracy. We aimed to evaluate the performance of claims‐based algorithms for glucocorticoid use compared to self‐report in an RA population. Methods: Participants with RA enrolled at seven Veterans Affairs Rheumatoid Arthritis (VARA) Registry sites were asked six questions as part of clinical care assessing current prednisone use and dose, recent use, “stockpiling,” and receiving prednisone outside the Department of Veterans Affairs (VA). Algorithms using VA prescription claims operationalized current use (active prescription on date of self‐report assessment), current dose (that prescription's mean dose), and recent use (active course overlapping the prior 30 or 90 days). We assessed performance characteristics and agreement, benchmarked on self‐report. Results: Of 284 participants, 13% reported current prednisone use and 20% reported 90‐day use. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.70, 0.98, 0.84, and 0.96, respectively, for current use and 0.71, 0.92, 0.72, and 0.92, respectively, for 90‐day use. Cohen's κ was 0.68 for current use and 0.63 for 90‐day use. Among participants reporting ≤5 mg/day, agreement for dose was high (weighted κ 0.67). One in four participants reported a stockpile, and one in four reported receiving prednisone from a non‐VA provider. Conclusion: Algorithms derived from VA claims detecting prednisone prescriptions have high validity compared to patient self‐report. The modest sensitivity of these algorithms may reflect stockpiling and non‐VA prescriptions. These findings form a basis for contextualizing real‐world studies of glucocorticoid use in RA and improve clinical estimation of glucocorticoid use not captured in claims.
- 24 April 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (11) , 1393
Withholding acetaminophen for older adults with osteoarthritis? Not so fast: comment on the article by Kaur et al
- 24 April 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (11) , 1393
Withholding acetaminophen for older adults with osteoarthritis? Not so fast: comment on the article by Kaur et al
- Open Access
- 7 April 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (8) , 971-980
Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Objective: Rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) is a significant cause of morbidity and mortality among patients with RA, yet effective risk stratification for RA‐ILD is lacking. We sought to characterize unique peripheral blood biomarker signatures in RA that could improve RA‐ILD discrimination beyond clinical and genetic risk factors.Methods: We performed a cross‐sectional study of participants in the Veterans Affairs Rheumatoid Arthritis Registry. ILD was validated through systematic record review. Autoantibodies (n = 14), proinflammatory cytokines/chemokines (n = 36), adipokines (n = 3), alarmins (n = 3), and matrix metalloproteinases (n = 9) were measured from banked serum or plasma. MUC5B rs35705950 genotyping was obtained via microarray. Principal component (PC) analysis was performed to derive unique biomarker signatures. Logistic regression was used to compare models predicting RA‐ILD presence using combinations of clinical, peripheral biomarker, and genetic variables.Results: Among 2,001 participants with RA (88.7% male, mean age 63.7 years), 121 (6.4%) had RA‐ILD. A total of 15 PCs were identified, with 8 significantly associated with RA‐ILD after adjusting for clinical factors. These eight included biomarker themes of innate and allergic responses, autoantibodies (anti–cyclic citrullinated peptide, rheumatoid factor, anti–malondialdehyde‐acetaldehyde adduct), adipokines, alarmins, tissue remodeling, and neutrophil chemotaxis. Models with PCs (area under the receiver operating characteristic curve [AUC] 0.739) and PCs with MUC5B (AUC 0.751) outperformed clinical risk factors alone (AUC 0.630; P < 0.001).Conclusion: Peripheral biomarker signatures are associated with RA‐ILD and improve RA‐ILD identification beyond clinical risk factors. In addition to demonstrating the potential for peripheral biomarkers to aid RA‐ILD risk stratification, these findings suggest diverse pathways are involved in RA‐ILD pathogenesis. image
- 7 April 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (8) , 971-980
Open AccessPeripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Objective: Rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) is a significant cause of morbidity and mortality among patients with RA, yet effective risk stratification for RA‐ILD is lacking. We sought to characterize unique peripheral blood biomarker signatures in RA that could improve RA‐ILD discrimination beyond clinical and genetic risk factors.Methods: We performed a cross‐sectional study of participants in the Veterans Affairs Rheumatoid Arthritis Registry. ILD was validated through systematic record review. Autoantibodies (n = 14), proinflammatory cytokines/chemokines (n = 36), adipokines (n = 3), alarmins (n = 3), and matrix metalloproteinases (n = 9) were measured from banked serum or plasma. MUC5B rs35705950 genotyping was obtained via microarray. Principal component (PC) analysis was performed to derive unique biomarker signatures. Logistic regression was used to compare models predicting RA‐ILD presence using combinations of clinical, peripheral biomarker, and genetic variables.Results: Among 2,001 participants with RA (88.7% male, mean age 63.7 years), 121 (6.4%) had RA‐ILD. A total of 15 PCs were identified, with 8 significantly associated with RA‐ILD after adjusting for clinical factors. These eight included biomarker themes of innate and allergic responses, autoantibodies (anti–cyclic citrullinated peptide, rheumatoid factor, anti–malondialdehyde‐acetaldehyde adduct), adipokines, alarmins, tissue remodeling, and neutrophil chemotaxis. Models with PCs (area under the receiver operating characteristic curve [AUC] 0.739) and PCs with MUC5B (AUC 0.751) outperformed clinical risk factors alone (AUC 0.630; P < 0.001).Conclusion: Peripheral biomarker signatures are associated with RA‐ILD and improve RA‐ILD identification beyond clinical risk factors. In addition to demonstrating the potential for peripheral biomarkers to aid RA‐ILD risk stratification, these findings suggest diverse pathways are involved in RA‐ILD pathogenesis. image
- 28 November 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (1) , 23-29
Escalation to Biologics After Methotrexate Among US Veterans With Rheumatoid Arthritis Grouped by Rural Versus Urban Areas
Objective: Racial and ethnic disparities in rheumatoid arthritis (RA) outcomes are well recognized. However, whether disparities in RA treatment selection and outcomes differ by urban versus rural residence, independent of race, have not been studied. Our objective was to evaluate whether biologic disease‐modifying antirheumatic drug (bDMARD) initiation after methotrexate administration differs by rural versus urban residence among veterans with RA.Methods: In this retrospective cohort study using national US Veterans Affairs (VA) databases, we identified adult patients with RA based on the presence of diagnostic codes and DMARD administration. We included patients receiving an initial prescription of methotrexate (index date) between 2005 and 2014, with data through 2016 used for follow‐up. Urban–rural status was categorized using the Veteran Health Administration's Urban/Rural classification. Our primary outcome of interest was time to biologic initiation within two years of starting methotrexate. Multivariable Cox proportional hazards models were conducted adjusting for demographics, comorbidities, and rheumatoid factor or anti‐cyclic citrullinated peptide positivity.Results: Among 17,395 veterans with RA (88% male, 42% with rural residence) fulfilling eligibility criteria, 3,259 (19%) initiated a biologic within the first two years of follow‐up. In multivariable models, residence in an urban area was associated with a statistically significant higher biologic administration compared to rural areas (adjusted hazard ratio 1.10 [95% confidence interval 1.02–1.18]).Conclusion: Our study found only modest differences in the initiation of biologic therapies among rural‐ versus urban‐residing veterans with RA in the VA health care system. These findings suggest that disparities are not easily explained by rurality within the VA health care system.
- 28 November 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (1) , 23-29
Escalation to Biologics After Methotrexate Among US Veterans With Rheumatoid Arthritis Grouped by Rural Versus Urban Areas
Objective: Racial and ethnic disparities in rheumatoid arthritis (RA) outcomes are well recognized. However, whether disparities in RA treatment selection and outcomes differ by urban versus rural residence, independent of race, have not been studied. Our objective was to evaluate whether biologic disease‐modifying antirheumatic drug (bDMARD) initiation after methotrexate administration differs by rural versus urban residence among veterans with RA.Methods: In this retrospective cohort study using national US Veterans Affairs (VA) databases, we identified adult patients with RA based on the presence of diagnostic codes and DMARD administration. We included patients receiving an initial prescription of methotrexate (index date) between 2005 and 2014, with data through 2016 used for follow‐up. Urban–rural status was categorized using the Veteran Health Administration's Urban/Rural classification. Our primary outcome of interest was time to biologic initiation within two years of starting methotrexate. Multivariable Cox proportional hazards models were conducted adjusting for demographics, comorbidities, and rheumatoid factor or anti‐cyclic citrullinated peptide positivity.Results: Among 17,395 veterans with RA (88% male, 42% with rural residence) fulfilling eligibility criteria, 3,259 (19%) initiated a biologic within the first two years of follow‐up. In multivariable models, residence in an urban area was associated with a statistically significant higher biologic administration compared to rural areas (adjusted hazard ratio 1.10 [95% confidence interval 1.02–1.18]).Conclusion: Our study found only modest differences in the initiation of biologic therapies among rural‐ versus urban‐residing veterans with RA in the VA health care system. These findings suggest that disparities are not easily explained by rurality within the VA health care system.